Overview:
FDA
inspections under the new QMSR can look and feel different—not just in what
investigators prioritize, but also in what information they can request and
review. In this webinar, we will explain how QMSR has expanded FDA’s inspection
rights and what that means in practical terms for regulated companies.
Specifically, we’ll clarify the processes and documents FDA is now allowed to
inspect, including management reviews and supplier and internal audits, and
what FDA is expecting to see when these records are requested.
FDA
is required to conduct an inspection every two years, and preparation directly
impacts how smoothly that inspection goes. A company that is prepared is less
likely to receive 483’s than an unprepared company. If a 483 is issued, a
well-informed and timely response can lessen the chances of receiving a Warning
Letter. We will break down what “prepared” looks like: how to assign
responsibilities, how to organize people and information, and how to support an
inspection so responses are consistent, accurate, and controlled.
We’ll
also describe the new remote Regulatory Assessment, which allows FDA to request
documents for review prior to an inspection—enabling investigators to focus the
on-site portion on suspect areas. By attending, you will learn how to prepare
for a QMSR-based inspection and how to respond if you receive a 483 or Warning
Letter. We will cover inspection types, planning and role assignments, facility
setup (front room/back room), the value of internal and mock audits, how to
conduct yourself during an inspection (including what not to sign), the
inspection process itself, and the documentation FDA can now require under
QMSR.
Areas
covered in the session:
- New
FDA inspection rights under the QMSR
- Personnel
preparation
- Procedure
to follow during audit-what to do/ what not to do
- Facility
requirements to support inspection
- Behavior
during inspection-what not to sign
- Internal/
mock audits
- 483/
Warning Letter response
Why
should you attend?
FDA
inspections under the new QMSR can involve broader document access and
different inspection focus areas than many companies are used to. This session
helps you understand what FDA can now ask to see—including management reviews
and internal/supplier audit records—and what that means for your day-to-day
inspection readiness.
You’ll
also learn how to prepare in a practical, organized way: who should do what
before and during the inspection, how to set up the front room/back room, how
to manage requests and communications, and how your team should conduct
themselves while FDA is on site.
Finally,
if you do receive a 483 (or a Warning Letter), this webinar walks through how
to respond appropriately and reduce the chance of escalation. You’ll also learn
how the remote Regulatory Assessment works, so you’re better prepared when FDA
requests documents before the inspection and uses them to narrow in on suspect
areas.
Handouts:
Attendees
will gain access to exclusive handouts, including presentation materials
provided by the speaker and additional resources developed by Amorit Education
to support post-session implementation, such as:
- Inspection readiness checklist
- FDA
Inspection Request Log + Document Production Workflow Template (PDF)
- Remote
Regulatory Assessment Response Playbook (PDF)
- Inspection
Roles & Responsibilities (RACI) + Escalation Tree (PDF)
Who
will benefit?
This
webinar will benefit professionals responsible for FDA inspection readiness,
QMS compliance under QMSR, audit programs, and managing inspection
communications and outcomes (including 483 and Warning Letter responses). Those
include:
- VP,
Quality Assurance (QA)
- Director
of Quality Assurance
- Quality
Systems Manager / Director
- Quality
Compliance Manager
- Regulatory
Affairs Director / Manager
- Director
of Regulatory Compliance
- Head
of Inspection Readiness
- FDA
Inspection Program Manager / Inspection Coordinator
- CAPA
Manager / CAPA Program Owner
- Document
Control Manager / Document Management Lead
- Internal
Audit Manager / Lead Auditor
- Supplier
Quality Manager / Supplier Quality Engineer (SQE)
- Quality
Audit Program Manager
- Quality
Engineering Manager
- Manufacturing
Quality Manager
- Validation
/ Compliance Manager (CSV/CSA/Quality)
- Quality
Risk Management Manager
- Complaint
Handling / Postmarket Surveillance Manager
- Operations
/ Plant Manager (site inspection lead)
- Quality
Management Representative (QMR) / Management Representative
- General
Manager / Site Head (for regulated facilities)
Edwin Waldbusser is a consultant retired from industry after 20 years in management of development of medical devices (5 patents). He has been consulting in the US and internationally in the areas of design control, risk analysis and software validation for the past 11 years.
Mr. Waldbusser has a BS in Mechanical Engineering and an MBA. He is a Lloyds of London certified ISO 9000 Lead Auditor and a member of the Thomson Reuters Expert Witness network.
Enrollment Options
Tags: FDA Compliance, QMSR, Inspection Readiness, Medical Device Quality, Quality Systems, Internal Audits, Supplier Audits, Remote Regulatory Assessment, 483 Response, Warning Letter Response, Edwin Waldbusser, February 2026, Webinar

